Maladie de Sjögren : manifestations extra-glandulaires et prise en charge thérapeutique

Web conference of February 19, 2026 Sjögren's syndrome: extraglandular manifestations and therapeutic management, by Professor Xavier Mariette, Head of the Immuno-Rheumatology Department, Director of the Autoimmunity Team, Immunology of Biral, Autoimmune, Hematological and Bacterial Diseases Laboratory, Bicêtre Hospital This web conference is also available in English:    • Sjögren disease : Treatment of extra-gland...   🔎 Find this web conference here: https://www.fai2r.org/videotheque-par... 00:23 Declaration of conflicts of interest 00:25 Clinical manifestations of Sjögren's syndrome 00:53 Complications 01:33 ACR/EULAR 2016 Classification Criteria for Primary Sjögren's Syndrome 02:00 Serum Autoantibodies 02:25 Assessing Disease Activity: An EULAR Collaboration 02:47 ESSPRI: Patient-Reported Index of European Sjögren's Syndrome 03:07 ESSDAI: Disease Activity Index of European Sjögren's Syndrome 03:18 ESSDAI and ESSPRI: Activity Thresholds and Minimal Clinically Significant Improvement (MCII) 04:13 New Clinical Criterion: A Tool for Assessing Treatment Response in Sjögren's Syndrome (STAR) 06:14 General Treatment of Dryness Pilocarpine and cevimeline: meta-analysis of randomized controlled trials 06:35 Pilocarpine and cevimeline 06:58 Symptomatic treatment 07:44 Pathophysiology 09:26 How to target type 1 IFN? 10:40 How to target type 2 IFN? 12:16 How to target both type 1 and type 2 IFN? 12:47 Combination of classic drugs targeting both B and T cells: HCQ + leflunomide 12:56 Main results of the RepurpSS-I LEF/HCQ study 13:20 NECESSITY clinical trial 14:27 How to target B cells? 15:40 Obinutuzumab: A novel anti-CD20 antibody 15:52 Background: Anti-drug antibodies (ADAbs) targeting rituximab 17:05 BAFF: A key cytokine in autoimmune B cell activation 18:31 Increase in serum BAFF after rituximab 20:02 Mechanistic biomarker: Depletion of CD20+ B cells in salivary gland biopsies 20:28 Efficacy: Analysis of responders according to ESSDAI (population that completed the study) 21:18 Ianalumab: An anti-BAFF-R antibody combining B cell depletion and BAFF/BAFF-R inhibition 21:58 Ianalumab: Study design 22:04 Ianalumab in Sjögren's syndrome: Change in ESSDAI from baseline to completion Week 24 shows a statistically significant dose-response relationship 22:22 ESSDAI – efficacy at week 24 23:20 Rather than destroying B cells: decrease their activity by modulating the CD40/CD40L co-activation pathway 25:41 Signature of three cell subtypes in salivary glands 27:22 BAFF and APRIL: two key cytokines in plasma cell activation 28:26 Engaging T lymphocytes: bispecific anti-CD3/BCMA antibody 29:13 Nipocalimab: an anti-FcRn antibody 30:37 Lymphomas and Sjögren's syndrome 30:56 Classic predictors of lymphoma in Sjögren's syndrome 31:13 Role of immune complexes in RF B cell stimulation 31:37 In clinical practice? 32:10 PET scan and lymphoma diagnosis in Sjögren's syndrome 32:24 Impact of lymphoma treatment strategy on hematological response and autoimmune disease activity in Sjögren's patients who develop lymphoma 33:34 Key takeaways 34:19 Acknowledgments